Secondary leukaemia after MMM combined modality therapy for breast carcinoma.
Philpott
N J
NJ
Bevan
D H
DH
Gordon-Smith
E C
EC
D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced*; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D016685:Mitomycin / Q000009:adverse effects; D008942:Mitoxantrone / Q000009:adverse effects; D016609:Neoplasms, Second Primary / Q000139:chemically induced*
D016685:Mitomycin; D008942:Mitoxantrone; D008727:Methotrexate